See Full Report below….
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our
Members in the last 3 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our members gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49%
April 11th, 2016 (NASDAQ: FNJN) opened at $1.07 hit $1.76 within 3 days for 64% gains for our members.
For our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time.
We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
MannKind Corporation (NASDAQ:MNKD) last reported EPS for the quarter of $-0.04 for the period ending on 2015-12-31. Leading up to the earnings report, covering Street analysts used for the Zacks Research consensus estimate were looking for a quarterly earnings per share of $-0.05. The difference between the numbers resulted in a surprise factor of 20%. The company’s present impact score is 82. The stock may be more likely to have increased movement on reported news if it has been issued a high impact score. Beta Research has placed a news sentiment score of 0 on the stock. On a scale from 1 to -1, a positive score may represent a favorable news sentiment. The opposite is the case for a negative news sentiment score.
Taking a peek at where the stock might be headed in the future, analysts have a consensus target price of $3.3 on the stock. The most bullish brokerage firm has a $9 target, while the most bearish sees the stock headed towards $0.05. This is according to the 4 estimates taken into consideration by Zacks Research.
In terms of Buy/Sell recommendations, analysts have a consensus rating of 3.4. This is according to a simplified scale where 1 represents a Strong Buy and 5 a Strong Sell recommendation. There were 4 recommendations taking into account in order to arrive at this number. Of the 4, 2 have a Strong Buy rating and 0 are rating it a Buy.
For the upcoming quarter, early predictions are anticipating that the company will post earnings of $-0.05 per share.
MannKind Corporation (MannKind) is a development-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. The Company’s product candidate, AFREZZA (insulin human) inhalation powder, is insulin that is in late-stage clinical investigation for the treatment of adults with type I or type II diabetes for the control of hyperglycemia. The AFREZZA inhalation powder is centered on a class of potential of hydrogen (pH)-sensitive organic molecules. AFREZZA utilizes its Technosphere formulation technology. As of December 31, 2011, MannKind had not generated any product revenues. As of December 31, 2011, the AFREZZA clinical program had involved 61 different studies of AFREZZA and over 5,600 adult patients.
Source: Franklin Independent